Please assess the completion status of the following clinical trial:

Trial Title: Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Biopsy proven NSCLC~2. Stage IIIB or IV measurable disease burden after routine staging work up.~3. Documented disease progression after first or second line chemotherapy. This will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST)~4. Ability to give informed consent and willingness to adhere to study protocol~5. Ability to take oral medication~6. Age ≥ 18 years.~7. Eastern Cooperative Oncology Group (ECOG) Performance Status between 0-2~8. Adequate hematological, hepatic and renal function defined as below:~   granulocyte count \> 1500/mm3, platelet count \> 100.000/mm3, serum creatinine \< 1.5; bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) at or below institutional upper limit of normal (IULN). All lab values should be obtained within 14 days of registration.~9. Patients have to have recovered from any toxic effects of prior chemotherapy or radiation therapy to a Grade 1 or less (except from alopecia). Enrollment should occur no less than 28 days after completion of prior therapy.~10. Ability to comply with the use of contraceptive measures starting 1 week before and ending 2 weeks after the last dose of study drug.~Exclusion Criteria:~1. Liver or kidney problems that would interfere with metabolism of study drug. This includes any preexisting elevation of AST, ALT, ALP or bilirubin.~2. Any condition that would hamper informed consent or ability to comply with the study protocol~3. Participation in another research study in the last three months~4. Known malignancy at any site other than NSCLC~5. Recent consumption of green tea (5 or more cups per day within one week of study enrollment)~6. Significant history of cardiac disease, e.g. uncontrolled hypertension, unstable angina, congestive-heart failure, myocardial infarction within the last six months or ventricular arrhythmias requiring medication.~7. Presence of metastatic brain lesions~8. Documented history of bleeding diathesis~9. Need to be on therapeutic anticoagulation~10. Pregnant and lactating women~11. Patients with a known seizure disorder who are taking Phenytoin, Carbamazepine or Phenobarbital~12. Patients taking medications known to interfere with erlotinib metabolism as listed below.~    * Atazanavir~   * Clarithromycin~   * Indinavir~   * Itraconazole~   * Ketoconazole~   * Nefazodone~   * Nelfinavir~   * Ritonavir~   * Saquinavir~   * Telithromycin~   * Troleandomycin~   * Voriconazole~   * Rifampicin~   * Rifabutin~   * Rifapentine~   * Phenytoin~   * Carbamazepine~   * Phenobarbital~   * St John's Wort.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I/II (Type: EXPERIMENTAL): Phase I: Polyphenon E + Erlotinib - Polyphenon E 200, 400 and 800 mg/day dose levels evaluated in a step-wise manner with Erlotinib 150 mg/day to establish Maximum Tolerated Dose (MTD) of Polyphenon E. Phase II consists of MTD of Polyphenon E established in Phase I, administered alone for two weeks and thereafter together with Erlotinib 150 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).